Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
109.92
+0.62 (0.57%)
At close: Jul 28, 2025, 4:00 PM
108.80
-1.12 (-1.02%)
After-hours: Jul 28, 2025, 4:03 PM EDT

Company Description

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.

The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

The company markets and distributes its products directly to customers, as well as through life-science distributors.

Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Illumina, Inc.
Illumina logo
CountryUnited States
Founded1998
IPO DateJul 28, 2000
IndustryDiagnostics & Research
SectorHealthcare
Employees10,370
CEOJacob Thaysen

Contact Details

Address:
5200 Illumina Way
San Diego, California 92122
United States
Phone858 202 4500
Websiteillumina.com

Stock Details

Ticker SymbolILMN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001110803
CUSIP Number452327109
ISIN NumberUS4523271090
Employer ID33-0804655
SIC Code3826

Key Executives

NamePosition
Jacob Thaysen Ph.D.Chief Executive Officer and Director
Ankur Dhingra CPAChief Financial Officer
Kevin Carl PegelsChief of Global Operations
Dr. Steven Barnard Ph.D.Chief Technology Officer
Stephanie CamposPresident
Scott EricksenVice President and Chief Accounting Officer
Mark FieldChief Information Officer
Brian BlanchettVice President of Finance and Treasurer and Interim Head of Investor Relations
Scott DaviesChief Legal Officer
Jakob WedelChief Strategy and Corporate Development Officer

Latest SEC Filings

DateTypeTitle
Jun 23, 20258-KCurrent Report
May 23, 20258-KCurrent Report
May 16, 2025SDForm - SD
May 13, 2025SCHEDULE 13G/AFiling
May 9, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
May 6, 2025144Filing
Apr 16, 2025DEFR14AFiling
Apr 9, 2025ARSFiling
Apr 9, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material